- Home
- SPRO vs FLL Comparison
SPRO vs FLL Comparison
Compare SPRO & FLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- FLL
- Stock Information
- Founded
- SPRO 2013
- FLL 1987
- Country
- SPRO United States
- FLL United States
- Employees
- SPRO N/A
- FLL N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- FLL Hotels/Resorts
- Sector
- SPRO Health Care
- FLL Consumer Discretionary
- Exchange
- SPRO Nasdaq
- FLL Nasdaq
- Market Cap
- SPRO 121.0M
- FLL 133.3M
- IPO Year
- SPRO 2017
- FLL 1993
- Fundamental
- Price
- SPRO $1.90
- FLL $3.39
- Analyst Decision
- SPRO Buy
- FLL Buy
- Analyst Count
- SPRO 4
- FLL 5
- Target Price
- SPRO $5.00
- FLL $5.80
- AVG Volume (30 Days)
- SPRO 323.5K
- FLL 124.6K
- Earning Date
- SPRO 11-13-2025
- FLL 11-05-2025
- Dividend Yield
- SPRO N/A
- FLL N/A
- EPS Growth
- SPRO N/A
- FLL N/A
- EPS
- SPRO N/A
- FLL N/A
- Revenue
- SPRO $48,576,000.00
- FLL $297,653,000.00
- Revenue This Year
- SPRO N/A
- FLL $4.96
- Revenue Next Year
- SPRO N/A
- FLL $8.15
- P/E Ratio
- SPRO N/A
- FLL N/A
- Revenue Growth
- SPRO N/A
- FLL 8.24
- 52 Week Low
- SPRO $0.51
- FLL $2.86
- 52 Week High
- SPRO $3.22
- FLL $5.59
- Technical
- Relative Strength Index (RSI)
- SPRO 40.19
- FLL 41.13
- Support Level
- SPRO $1.91
- FLL $3.29
- Resistance Level
- SPRO $2.18
- FLL $3.55
- Average True Range (ATR)
- SPRO 0.09
- FLL 0.18
- MACD
- SPRO 0.00
- FLL 0.02
- Stochastic Oscillator
- SPRO 11.94
- FLL 18.18
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About FLL Full House Resorts Inc.
Full House Resorts Inc owns, operates, develops, manages, and invests in casinos and related hospitality and entertainment facilities. It offers facilities related to gaming, hotel, dining, entertainment, retail, and other amenities. The group's reportable segments are Midwest & South, West, and Contracted Sports Wagering, It generates the majority of its revenue from the Midwest & South segment which includes Silver Slipper Casino and Hotel, Rising Star Casino Resort, and American Place. The west segment includes Grand Lodge, Stockman's Casino, Bronco Billy's Casino and Hotel, and Chamonix Casino Hotel. The Contracted Sports Wagering segment comprises on-site and online sports wagering skins.